GlassScriptPhysician profile
Diane M Kushnar
NPI 1659473858
$8,719.71
in general payments reported to CMS, 2019-2025
33 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $1,255 · 2021: $966 · 2022: $1,291 · 2023: $1,244 · 2024: $1,595 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,006.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,890.96 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Supernus Pharmaceuticals, INC. | $1,463.10 | 2022-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,080.80 | 2021-2025 | |
| Novo Nordisk INC | $974.81 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $804.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $256.69 | 2019-2020 | |
| Amgen INC. | $236.05 | 2019-2022 | |
| Amarin Pharma, INC. | $204.10 | 2020-2021 | |
| Corium, LLC | $186.84 | 2022-2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.55 | 2019-2023 | Tradjenta, Jardiance |
| Merck Sharp & Dohme LLC | $152.69 | 2019-2021 | |
| Shire North American Group INC | $138.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $121.84 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $115.39 | 2025 | The Cologuard Plus Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $109.19 | 2019-2020 | |
| Abbott Laboratories | $100.59 | 2021-2025 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $80.94 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $57.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.29 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $50.80 | 2019-2021 | |
| Horizon Therapeutics Plc | $50.67 | 2023 | Krystexxa |
| Esperion Therapeutics, INC. | $47.41 | 2020-2021 | |
| Dexcom, INC. | $36.60 | 2023-2024 | Dexcom G6 Transmitter |
| Eisai INC. | $34.04 | 2020 | |
| Pfizer INC. | $31.62 | 2019 | |
| Vivus LLC | $31.30 | 2021 | |
| Gilead Sciences, INC. | $28.84 | 2020 | |
| Genentech USA, INC. | $23.93 | 2019 | |
| Echosens North America, INC. | $20.74 | 2025 | Fibroscan |
| Tris Pharma INC | $17.23 | 2025 | Dyanavel Xr |
| Ultragenyx Pharmaceutical INC. | $14.04 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.92 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Kushnar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.